On Wednesday, biotechnology firm MAIA Biotechnology, Inc. reported encouraging results regarding efficacy in their third-line treatment during the phase 2 clinical trial. The trial combined THIO with the immune checkpoint inhibitor, cemiplimab, for treatment of non-small cell lung cancer (NSCLC), the most prevalent type of lung cancer.
In the trial, nearly 38 percent of NSCLC patients who previously did not respond to treatment with immune checkpoint inhibitors showed a significant overall response rate.
MAIA Biotechnology expressed that they expected the THIO-101 trial to be the first successfully completed clinical study to utilize a telomere-targeting agent in the field of cancer drug research and treatment.
Presently, shares of Maia Biotechnology are listed on the New York Stock Exchange. They are currently priced at $1.6, marking an 8.11% increase in value.
